Luna's gaseous emboli counter:
This article was originally published in Clinica
Executive Summary
Luna Innovations has received US FDA 510(k) market clearance for its ultrasound-based technology for noninvasively counting and measuring gaseous emboli in real-time during cardiopulmonary bypass surgery, the EDAC (emboli detection and classification) quantifier. One of the most significant risks associated with emboli is brain damage caused by gaseous microemboli introduced into the cerebral blood flow during cardiopulmonary bypass procedures, said the Roanoke, Virginia firm. EDAC can provide surgeons with data on the quantity and volume of gaseous emboli at multiple locations in extracorporeal circuits during a procedure, enabling them to reduce the neurocognitive side-effect problems associated with cardiopulmonary bypass.